Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

Dendritic cells are regarded as the most effective antigen presenting cells and coordinators of the immune response and therefore suitable as vaccine basis. Here we present results from a clinical study in which patients with malignant melanoma (MM) with verified progressive disease received vaccination with autologous monocyte-derived mature dendritic cells (DC) pulsed with p53, survivin and telomerase-derived peptides (HLA-A2+ patients) or with autologous/allogeneic tumor lysate (HLA-A2(-) patients) in combination with low-dose interleukin (IL)-2 and interferon (IFN)-alpha2b.

General information
State: Published
Organisations: University Hospital Herlev, Copenhagen University Hospital, University of Copenhagen
Number of pages: 14
Pages: 721-734
Publication date: 2010
Peer-reviewed: Yes

Publication information
Journal: Cytotherapy
Volume: 12
Issue number: 6
ISSN (Print): 1465-3249
Ratings:
BFI (2018): BFI-level 1
Web of Science (2018): Indexed yes
BFI (2017): BFI-level 1
Scopus rating (2017): CiteScore 3.26 SJR 1.144 SNIP 0.967
Web of Science (2017): Impact factor 3.993
Web of Science (2017): Indexed yes
BFI (2016): BFI-level 1
Scopus rating (2016): CiteScore 3.39 SJR 1.213 SNIP 1.002
Web of Science (2016): Impact factor 3.203
Web of Science (2016): Indexed yes
BFI (2015): BFI-level 1
Scopus rating (2015): CiteScore 3.36 SJR 1.315 SNIP 0.926
Web of Science (2015): Impact factor 3.625
BFI (2014): BFI-level 1
Scopus rating (2014): CiteScore 3.06 SJR 1.193 SNIP 0.983
Web of Science (2014): Impact factor 3.293
BFI (2013): BFI-level 1
Scopus rating (2013): CiteScore 3.11 SJR 1.174 SNIP 0.994
Web of Science (2013): Impact factor 3.1
ISI indexed (2013): ISI indexed yes
BFI (2012): BFI-level 1
Scopus rating (2012): CiteScore 3.32 SJR 1.151 SNIP 0.975
Web of Science (2012): Impact factor 3.055
ISI indexed (2012): ISI indexed yes
BFI (2011): BFI-level 1
Scopus rating (2011): CiteScore 3.21 SJR 1.158 SNIP 0.822
Web of Science (2011): Impact factor 3.627
ISI indexed (2011): ISI indexed yes
BFI (2010): BFI-level 1
Scopus rating (2010): SJR 0.837 SNIP 0.75
Web of Science (2010): Impact factor 2.925